Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B study of pegylated interferon lambda + ribavirin + direct-acting antivirals vs Pegasys + ribavirin in chronic hepatitis C genotype 1
jRCT2080221455Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- May 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of peginterferon lambda-1a in chronic hepatitis C virus infection (5 arms), sponsored by Bristol Myers Squibb.
02
Drugs
peginterferon lambda-1a
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on jRCT2080221455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221455.